可切除结直肠肝转移的围手术期化疗与肝切除术。
Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases.
机构信息
1 Department of Multidisciplinary Treatment for Gastroenterological Cancer, Kumamoto University Hospital, Kumamoto, Japan ; 2 Department of Gastroenterological Surgery, Graduate School of Life Sciences, Kumamoto University, Kumamoto, Japan.
出版信息
Hepatobiliary Surg Nutr. 2015 Feb;4(1):72-5. doi: 10.3978/j.issn.2304-3881.2014.07.08.
Abstract
The role of perioperative chemotherapy in the management of initially resectable colorectal liver metastases (CRLM) is still unclear. The EPOC trial [the European Organization for Research and Treatment of Cancer (EORTC) 40983] is an important study that declares perioperative chemotherapy as the standard of care for patients with resectable CRLM, and the strategy is widely accepted in western countries. Compared with surgery alone, perioperative FOLFOX therapy significantly increased progression-free survival (PFS) in eligible patients or those with resected CRLM. Overall survival (OS) data from the EPOC trial were recently published in The Lancet Oncology, 2013. Here, we discussed the findings and recommendations from the EORTC 40983 trial.
摘要
围手术期化疗在可切除结直肠肝转移（CRLM）患者中的作用仍不明确。EPOC 试验[欧洲癌症研究与治疗组织（EORTC）40983]是一项重要的研究，该试验将围手术期化疗作为可切除 CRLM 患者的标准治疗方案，这一策略在西方国家得到广泛认可。与单纯手术相比，围手术期 FOLFOX 治疗可显著延长适合或切除 CRLM 患者的无进展生存期（PFS）。EPOC 试验的总生存（OS）数据最近发表于《柳叶刀肿瘤学》，2013 年。在此，我们对 EORTC 40983 试验的研究结果和建议进行了讨论。
相似文献
1
Perioperative chemotherapy and hepatic resection for resectable colorectal liver metastases.可切除结直肠肝转移的围手术期化疗与肝切除术。
Hepatobiliary Surg Nutr. 2015 Feb;4(1):72-5. doi: 10.3978/j.issn.2304-3881.2014.07.08.
2
Perioperative chemotherapy for resectable colorectal hepatic metastases-What does the EORTC 40983 trial update mean?可切除结直肠肝转移的围手术期化疗——EORTC 40983 试验更新意味着什么？
Hepatobiliary Surg Nutr. 2015 Feb;4(1):80-3. doi: 10.3978/j.issn.2304-3881.2014.08.05.
3
Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled PUMP trial.低危可切除结直肠癌肝转移患者中辅助性肝动脉灌注泵化疗联合切除术与单纯切除术的比较——多中心随机对照 PUMP 试验。
BMC Cancer. 2019 Apr 5;19(1):327. doi: 10.1186/s12885-019-5515-6.
4
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).结直肠肝转移切除术后高危患者辅助治疗的术后肝动脉化疗-一项随机 II/III 期试验-PACHA-01（NCT02494973）。
BMC Cancer. 2018 Aug 6;18(1):787. doi: 10.1186/s12885-018-4697-7.
5
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.单独手术或围手术期 FOLFOX 治疗可切除结直肠癌肝转移的随机 EORTC 研究 40983 中免疫反应对预后的影响。
Eur J Cancer. 2015 Nov;51(17):2708-17. doi: 10.1016/j.ejca.2015.08.014. Epub 2015 Sep 2.
6
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).预测因素分析可切除结直肠癌肝转移患者围手术期 FOLFOX 方案（EORTC 国际多中心临床试验 40983）的获益。
Ann Surg. 2012 Mar;255(3):534-9. doi: 10.1097/SLA.0b013e3182456aa2.
7
[Perioperative chemotherapy in patients with colorectal cancer liver metastasis].[结直肠癌肝转移患者的围手术期化疗]
Zhonghua Wei Chang Wai Ke Za Zhi. 2019 Apr 25;22(4):321-328. doi: 10.3760/cma.j.issn.1671-0274.2019.04.003.
8
Systematic review of systemic adjuvant, neoadjuvant and perioperative chemotherapy for resectable colorectal-liver metastases.可切除结直肠癌肝转移的全身辅助、新辅助和围手术期化疗的系统评价
HPB (Oxford). 2016 Jun;18(6):485-93. doi: 10.1016/j.hpb.2016.03.001. Epub 2016 Apr 20.
9
[Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].[术前化疗在结直肠癌肝转移手术治疗中的应用]
Magy Seb. 2013 Dec;66(6):325-30. doi: 10.1556/MaSeb.66.2013.6.4.
10
Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.通过区域化疗对不可切除的孤立性结直肠癌肝转移进行降期治疗。
Eur J Surg Oncol. 1999 Aug;25(4):381-8. doi: 10.1053/ejso.1999.0661.
引用本文的文献
1
Feasibility of Hepatic Artery Infusion Chemotherapy for Colorectal Liver Metastasis in an Indian Setting.肝动脉灌注化疗用于印度环境下结直肠癌肝转移的可行性
Indian J Surg Oncol. 2024 May;15(Suppl 2):275-280. doi: 10.1007/s13193-023-01871-0. Epub 2023 Dec 29.
2
Metachronous colorectal liver metastasis that occurred 10 years after laparoscopic colectomy: a case report.腹腔镜结肠切除术后10年发生的异时性结直肠癌肝转移：病例报告
Surg Case Rep. 2022 Aug 1;8(1):144. doi: 10.1186/s40792-022-01503-9.
3
A Real-World, Population-Based Analysis of the Outcomes of Colorectal Cancer Patients with Isolated Synchronous Liver or Lung Metastases Treated with Metastasectomy.一项基于真实世界的、以人群为基础的研究，分析了接受转移瘤切除术治疗的孤立性同步肝或肺转移结直肠癌患者的结局。
World J Surg. 2020 May;44(5):1604-1611. doi: 10.1007/s00268-019-05353-9.
4
Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin‑induced model of liver injury.甘草酸镁在奥沙利铂诱导的肝损伤模型中具有保肝作用。
Int J Mol Med. 2018 Oct;42(4):2020-2030. doi: 10.3892/ijmm.2018.3787. Epub 2018 Jul 19.
5
Preoperative Chemotherapy May Not Influence the Remnant Liver Regenerations and Outcomes After Hepatectomy for Colorectal Liver Metastasis.术前化疗可能不会影响结直肠癌肝转移肝切除术后残余肝的再生及预后。
World J Surg. 2018 Oct;42(10):3316-3330. doi: 10.1007/s00268-018-4590-1.
本文引用的文献
1
2
Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.可切除结直肠肝转移患者的系统化疗联合或不联合西妥昔单抗：New EPOC 随机对照试验。
Lancet Oncol. 2014 May;15(6):601-11. doi: 10.1016/S1470-2045(14)70105-6. Epub 2014 Apr 7.
3
Discrepancy between recurrence-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure.可切除结直肠癌肝转移患者无复发生存期与总生存期的差异：手术失败时间的潜在替代终点
Ann Surg Oncol. 2014 Jun;21(6):1817-24. doi: 10.1245/s10434-014-3504-1. Epub 2014 Feb 6.
4
Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.围手术期 FOLFOX4 化疗联合手术与单纯手术治疗结直肠癌可切除肝转移（EORTC 40983）：一项随机、对照、3 期临床试验的长期结果。
Lancet Oncol. 2013 Nov;14(12):1208-15. doi: 10.1016/S1470-2045(13)70447-9. Epub 2013 Oct 11.
5
Perioperative chemotherapy for resectable colorectal liver metastases: where now?可切除结直肠肝转移的围手术期化疗：现状如何？
Eur J Surg Oncol. 2013 Aug;39(8):807-11. doi: 10.1016/j.ejso.2013.04.002. Epub 2013 May 29.
6
Repeat hepatectomy for recurrent colorectal metastases.再次肝切除术治疗复发性结直肠转移瘤。
Br J Surg. 2013 May;100(6):808-18. doi: 10.1002/bjs.9088. Epub 2013 Mar 12.
7
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.结直肠癌肝转移的肿瘤外科处理：多学科国际共识。
Oncologist. 2012;17(10):1225-39. doi: 10.1634/theoncologist.2012-0121. Epub 2012 Sep 7.
8
Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983).预测因素分析可切除结直肠癌肝转移患者围手术期 FOLFOX 方案（EORTC 国际多中心临床试验 40983）的获益。
Ann Surg. 2012 Mar;255(3):534-9. doi: 10.1097/SLA.0b013e3182456aa2.
9
A nomogram predicting disease-free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepato-Biliary-Pancreatic Surgery.预测接受肝切除术治疗结直肠肝转移患者无病生存的列线图：日本肝胆胰外科学会肝脏外科研讨会项目的多中心数据收集。
J Hepatobiliary Pancreat Sci. 2012 Jan;19(1):72-84. doi: 10.1007/s00534-011-0460-z.
10
Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?围手术期化疗对单发、异时性结直肠癌肝转移是否有效？
Ann Surg. 2010 Nov;252(5):774-87. doi: 10.1097/SLA.0b013e3181fcf3e3.
Zotero 插件